Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BHCNASDAQ:BPMCNASDAQ:INDVNYSE:PBH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHCBausch Health Cos$6.80+2.1%$5.21$3.96▼$9.85$2.46B0.412.62 million shs2.33 million shsBPMCBlueprint Medicines$128.34+0.1%$111.05$73.04▼$129.54$8.28B0.891.31 million shs2.59 million shsINDVIndivior$14.66-0.5%$12.48$7.33▼$15.55N/A0.651.22 million shs1.46 million shsPBHPrestige Consumer Healthcare$80.28+0.5%$84.16$64.94▼$90.04$3.95B0.43304,032 shs560,973 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHCBausch Health Cos+3.81%+9.33%+47.46%+6.62%-4.16%BPMCBlueprint Medicines+0.05%-0.17%+26.72%+49.15%+18.93%INDVIndivior+5.66%+5.66%+15.88%+57.14%-8.56%PBHPrestige Consumer Healthcare-1.43%-5.35%-6.92%-7.08%+15.96%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBHCBausch Health Cos3.2193 of 5 stars0.93.00.04.03.23.30.6BPMCBlueprint Medicines1.7425 of 5 stars2.14.00.00.02.90.80.6INDVIndivior3.5935 of 5 stars2.63.00.00.03.21.73.1PBHPrestige Consumer Healthcare4.0021 of 5 stars2.34.00.03.53.01.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBHCBausch Health Cos 1.86Reduce$7.429.07% UpsideBPMCBlueprint Medicines 2.27Hold$128.06-0.22% DownsideINDVIndivior 3.25Buy$17.0015.96% UpsidePBHPrestige Consumer Healthcare 2.50Moderate Buy$93.3316.27% UpsideCurrent Analyst Ratings BreakdownLatest BHC, INDV, PBH, and BPMC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/30/2025INDVIndiviorCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$15.00 ➝ $22.006/17/2025BPMCBlueprint MedicinesWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold$143.00 ➝ $129.006/5/2025BPMCBlueprint MedicinesMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$102.00 ➝ $129.006/5/2025BPMCBlueprint MedicinesUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$88.00 ➝ $129.006/4/2025BPMCBlueprint MedicinesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong Sell ➝ Hold$83.00 ➝ $129.006/3/2025BPMCBlueprint MedicinesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$132.006/3/2025BPMCBlueprint MedicinesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold6/3/2025BPMCBlueprint MedicinesTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold6/3/2025BPMCBlueprint MedicinesCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold6/3/2025BPMCBlueprint MedicinesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Perform6/3/2025BPMCBlueprint MedicinesWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBHCBausch Health Cos$9.63B0.26$7.91 per share0.86($0.89) per share-7.64BPMCBlueprint Medicines$508.82M16.29N/AN/A$4.70 per share27.31INDVIndivior$1.19BN/A$1.81 per share8.10($2.52) per shareN/APBHPrestige Consumer Healthcare$1.14B3.49$5.24 per share15.32$37.04 per share2.17Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBHCBausch Health Cos-$46M-$0.11N/A1.46N/A-0.41%-540.45%5.26%7/30/2025 (Estimated)BPMCBlueprint Medicines-$67.09M-$2.47N/A197.45N/A-27.70%-64.60%-17.22%7/30/2025 (Estimated)INDVIndivior$2M-$0.31N/A8.57N/A-4.02%-97.29%15.74%7/24/2025 (Estimated)PBHPrestige Consumer Healthcare$214.60M$4.2918.7116.862.4018.86%12.87%6.78%8/6/2025 (Estimated)Latest BHC, INDV, PBH, and BPMC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/24/2025Q2 2025INDVIndivior$0.25N/AN/AN/AN/AN/A5/8/2025Q4 2025PBHPrestige Consumer Healthcare$1.30$1.32+$0.02$1.00$289.36 million$296.52 million5/1/2025Q1 2025BPMCBlueprint Medicines-$0.42-$0.74-$0.32$0.01$158.31 million$149.41 million4/24/2025Q1 2025INDVIndivior$0.22$0.41+$0.19$0.38$240.13 million$266.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBHCBausch Health CosN/AN/AN/AN/AN/ABPMCBlueprint MedicinesN/AN/AN/AN/AN/AINDVIndiviorN/AN/AN/AN/AN/APBHPrestige Consumer HealthcareN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBHCBausch Health CosN/A1.350.97BPMCBlueprint Medicines1.012.802.75INDVIndiviorN/A0.880.72PBHPrestige Consumer Healthcare0.554.202.82Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBHCBausch Health Cos78.65%BPMCBlueprint MedicinesN/AINDVIndivior60.33%PBHPrestige Consumer Healthcare99.95%Insider OwnershipCompanyInsider OwnershipBHCBausch Health Cos8.12%BPMCBlueprint Medicines4.21%INDVIndiviorN/APBHPrestige Consumer Healthcare1.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBHCBausch Health Cos20,700370.08 million340.03 millionOptionableBPMCBlueprint Medicines64064.58 million61.86 millionOptionableINDVIndivior1,051N/AN/ANot OptionablePBHPrestige Consumer Healthcare54049.42 million48.62 millionOptionableBHC, INDV, PBH, and BPMC HeadlinesRecent News About These CompaniesWhy Prestige Consumer Healthcare (PBH) is a Top Value Stock for the Long-TermJune 30 at 10:46 AM | zacks.comPrestige Consumer Healthcare Inc. (NYSE:PBH) Shares Sold by Allspring Global Investments Holdings LLCJune 28 at 6:48 AM | marketbeat.comPrestige Consumer Healthcare Inc. (NYSE:PBH) Receives Average Rating of "Moderate Buy" from AnalystsJune 27, 2025 | marketbeat.comPrestige Consumer Healthcare Inc. (NYSE:PBH) Position Increased by Bessemer Group Inc.June 26, 2025 | marketbeat.comAvior Wealth Management LLC Grows Holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH)June 22, 2025 | marketbeat.comAdvisor Resource Council Buys Shares of 27,337 Prestige Consumer Healthcare Inc. (NYSE:PBH)June 21, 2025 | marketbeat.comZacks Research Analysts Reduce Earnings Estimates for PBHJune 21, 2025 | americanbankingnews.comZacks Research Issues Pessimistic Outlook for PBH EarningsJune 19, 2025 | marketbeat.comBoston Trust Walden Corp Sells 12,345 Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH)June 19, 2025 | marketbeat.comAssenagon Asset Management S.A. Reduces Stock Position in Prestige Consumer Healthcare Inc. (NYSE:PBH)June 19, 2025 | marketbeat.comZacks Research Issues Positive Estimate for PBH EarningsJune 18, 2025 | marketbeat.comMedtech Products Inc. Issues Nationwide Recall of Little Remedies® Honey Cough Syrup Due to Microbial ContaminationJune 17, 2025 | globenewswire.com7,572 Shares in Prestige Consumer Healthcare Inc. (NYSE:PBH) Bought by NorthCrest Asset Manangement LLCJune 15, 2025 | marketbeat.comShould You Continue to Hold Prestige Consumer Stock in Your Portfolio?June 11, 2025 | zacks.comWedge Capital Management L L P NC Trims Holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH)June 10, 2025 | marketbeat.comPrestige Consumer Healthcare Inc. to Present at the Oppenheimer Annual Consumer Growth and ...June 9, 2025 | gurufocus.comPrestige Consumer Healthcare Inc. to Present at the Oppenheimer Annual Consumer Growth and E-Commerce ConferenceJune 9, 2025 | globenewswire.comOlstein Capital Management L.P. Sells 11,000 Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH)June 9, 2025 | marketbeat.comPrestige Consumer Healthcare Inc. (NYSE:PBH) Holdings Lowered by Rhumbline AdvisersJune 9, 2025 | marketbeat.comMillennium Management LLC Trims Stake in Prestige Consumer Healthcare Inc. (NYSE:PBH)June 8, 2025 | marketbeat.comCongress Asset Management Co. Buys 82,838 Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH)June 7, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBHC, INDV, PBH, and BPMC Company DescriptionsBausch Health Cos NYSE:BHC$6.80 +0.14 (+2.10%) Closing price 03:59 PM EasternExtended Trading$6.89 +0.09 (+1.32%) As of 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.Blueprint Medicines NASDAQ:BPMC$128.34 +0.16 (+0.12%) Closing price 04:00 PM EasternExtended Trading$129.54 +1.19 (+0.93%) As of 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.Indivior NASDAQ:INDV$14.66 -0.08 (-0.54%) Closing price 04:00 PM EasternExtended Trading$14.67 +0.01 (+0.07%) As of 06:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.Prestige Consumer Healthcare NYSE:PBH$80.28 +0.43 (+0.53%) Closing price 03:59 PM EasternExtended Trading$80.25 -0.03 (-0.03%) As of 04:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 2 Reasons to Buy Trade Desk Stock Now and 1 Warning Sign Toast Stock: A Fast-Growing Mid-Cap Eyeing Further Upside Breakout Alert: Disney Stock Hits Multi-Year High 2 Under the Radar Space & Defense Stocks With Huge Potential Palantir’s $100M Nuclear OS Pact Boosts Bullish Case Forget IBM: Accenture’s AI Momentum Is Your Next Buy Joby Stock Soars as Piloted Flights in Dubai Signal a New Era Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.